Affiliation: AstraZeneca R and D
- Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorderKrithika Rajagopalan
Health Economics Outcomes Research, AstraZeneca Pharmaceuticals, Wilmington, DE 19850 5437, USA
Curr Med Res Opin 22:443-52. 2006..To compare the cost and utilization of health care services for various comorbid conditions among employees with bipolar disorder (BPD) and two other population cohorts: employees without BPD and employees with other mental disorders (OMD)...
- Employee costs before and after treatment initiation for bipolar disorderRichard A Brook
Retrospective Analysis, The JeSTARx Group, Newfoundland, NJ 07435 1710, USA
Am J Manag Care 13:179-86. 2007..To examine pretreatment and posttreatment total medical costs and overall mental healthcare costs for patients with bipolar disorder (BPD) treated with different medication regimens (alone and in combination) vs an untreated (UnTx) cohort...
- Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eyeKrithika Rajagopalan
AstraZeneca Pharmaceuticals, Wilmington, DE 76134 2099, USA
Value Health 8:168-74. 2005....
- Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal studyJudith J Stephenson
HealthCore Inc, Wilmington, DE 19801, USA
Health Qual Life Outcomes 10:155. 2012..We investigated the impact of natalizumab on patient-reported outcomes (PROs) in a real-world setting...
- Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional surveySiddhesh A Kamat
1 HealthCore Inc, Wilmington, Delaware, USA 2 Biogen Idec, Cambridge, Massachusetts, USA
Patient 2:105-12. 2009..To assess multiple sclerosis (MS) patients' experience with natalizumab (TYSABRI, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) in a clinical practice setting...
- Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured populationSiddhesh A Kamat
HealthCore, Wilmington, Delaware 19801, USA
J Manag Care Pharm 14:631-42. 2008..Because the depressive episodes in bipolar disorder may be indistinguishable from those in major depressive disorder (MDD), misdiagnosis may occur...
- A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of lifeJean Endicott
New York State Psychiatric Institute, New York City, NY 10032, USA
Int Clin Psychopharmacol 22:29-37. 2007..Improved quality of life may enhance patient compliance, and assessment of quality of life should be incorporated into future clinical trials in bipolar depression...
- Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorderFrank D Gianfrancesco
HECON Associates, Inc, Montgomery Village, Maryland 20886, USA
Clin Ther 30:1358-74. 2008..Up to 48% of patients with bipolar disorder are either nonadherent or partially adherent to antipsychotic drug treatment. Medication adherence may differ by bipolar disorder subtype...
- Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trialsJ Jaime Caro
Caro Research Institute, Concord, MA 01742, USA
Curr Med Res Opin 22:2233-42. 2006..To present a tool that allows estimation of the budget impact of treatments for acute mania in bipolar I disorder from a US healthcare payer perspective...
- The effect of medication adherence on health care utilization in bipolar disorderKim H Lew
Health Informatics and Outcomes Research, Prescription Solutions, Irvine, California 92614 6223, USA
Manag Care Interface 19:41-6. 2006..98; 95% confidence interval, 1.38-2.84) and inpatient hospitalizations (odds ratio, 1.71; 95% confidence interval, 1.27-2.32), even after adjusting for age, gender, and comorbidity...
- The economic impact of bipolar disorder in an employed population from an employer perspectiveHarold H Gardner
Human Capital Management Services, Cheyenne, WY 82001, USA
J Clin Psychiatry 67:1209-18. 2006..To determine the economic impact of bipolar disorder on health benefit costs and health-related work absences from an employer perspective...
- Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychoticsFrank D Gianfrancesco
HECON Associates, Inc, Montgomery Village, MD 20886, USA
J Clin Psychiatry 67:222-32. 2006..This retrospective claims-based study evaluated treatment adherence among patients with bipolar or manic disorder treated with atypical and typical antipsychotics...
- Quality-of-life improvements in cataract patients with bilateral blue light-filtering intraocular lenses: clinical trialDerek Espindle
Mapi Values, Boston, Massachusetts, USA
J Cataract Refract Surg 31:1952-9. 2005....
- Lost time, absence costs, and reduced productivity output for employees with bipolar disorderNathan L Kleinman
HCMS Group, Cheyenne, Wyoming 82001, USA
J Occup Environ Med 47:1117-24. 2005..We sought to evaluate the incremental health-related lost work time and at-work productivity loss for employees with bipolar disorder (BPD)...
- The relative burden of dry eye in patients' lives: comparisons to a U.S. normative samplePolyxane Mertzanis
Mapi Values, Boston, Massachusetts 02108, USA
Invest Ophthalmol Vis Sci 46:46-50. 2005..To assess the relative burden of dry eye in daily life by comparing Short Form-36 (SF-36) responses from individuals with and without dry eye against U.S. norms...
- The economic burden of dry eye: a conceptual framework and preliminary assessmentPrabashni Reddy
Abt Associates Inc, 55 Wheeler Street, Cambridge, Massachusetts 02138, USA
Cornea 23:751-61. 2004..To develop a conceptual framework for analyzing the economic burden of dry eye and a preliminary assessment of key factors that contribute to that burden...